Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors

JCO Precision Oncology

Volumn 2017, Issue 1, 2017, Pages 1-13

  Panda, Anshuman ^a,c   Betigeri, Anil ^d   Subramanian, Kalyanasundaram ^d   Ross, Jeffrey S ^e   Pavlick, Dean C ^e   Ali, Siraj ^e   Markowski, Paul ^b   Silk, Ann ^a,b   Kaufman, Howard L ^a,b   Lattime, Edmund ^a   Mehnert, Janice M ^a,b   Sullivan, Ryan ^e   Lovly, Christine M ^f   Sosman, Jeffrey ^g   Johnson, Douglas B ^f   Bhanot, Gyan ^a,c   Ganesan, Shridar ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d Strand Life Sciences ^*  (India)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE CHECKPOINT ACTIVATION; IMMUNE CHECKPOINT THERAPY; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA SEQUENCE; SOLID MALIGNANT NEOPLASM; STOMACH ADENOCARCINOMA; THE CANCER GENOME ATLAS; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNOLOGY; UTERINE CERVIX CANCER; WHOLE EXOME SEQUENCING;

EID: 85050195420     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.17.00146     Document Type: Article

References (41)

1. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014
2. Van Allen EM, Miao D, Schilling B, et al: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207-211, 2015
3. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
4. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015
5. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
6. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
7. Ramos AH, Lichtenstein L, Gupta M, et al: Oncotator: Cancer variant annotation tool. Hum Mutat 36:E2423-E2429, 2015
8. Yoshihara K, Shahmoradgoli M, Martínez E, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612, 2013
9. Newman AM, Liu CL, Green MR, et al: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453-457, 2015
10. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
11. Black MM, Speer FD, Opler SR: Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance. Am J Clin Pathol 26:250-265, 1956
12. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
13. Nanda R, Chow LQM, Dees EC, et al: Pembrolizumab in patients with advanced triple-negative breast Cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460-2467, 2016
14. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma.NEngl J Med 373:1803-1813, 2015
15. Sen M, Katragadda S, Ravichandran A, et al: StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors. Cancer Med 6:883-901, 2017
16. Johnson DB, Frampton GM, Rioth MJ, et al: Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res 4:959-967, 2016
17. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218, 2013
18. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
19. Koo B-K, Spit M, Jordens I, et al: Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488:665-669, 2012
20. Deacu E, Mori Y, Sato F, et al: Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer Res 64:7690-7696, 2004
21. Rao S, Stadanlick JE, Cai KQ, et al: Loss of Rpl22 promotes tumor progression through regulation of angiogenesis. Cancer Res 75, 2015 (suppl 15; abstr 521)
22. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
23. Alexandrov LB: Understanding the origins of human cancer. Science 350:1175-1177, 2015
24. Brash DE: UV mutagenic photoproducts in Escherichia coli and human cells: A molecular genetics perspective on human skin cancer. Photochem Photobiol 48:59-66, 1988
25. Hernandez-Boussard TM, Hainaut P: A specific spectrum of p53 mutations in lung cancer from smokers: Review of mutations compiled in the IARC p53 database. Environ Health Perspect 106:385-391, 1998
26. Mehnert JM, Panda A, Zhong H, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126:2334-2340, 2016
27. Roberts SA, Lawrence MS, Klimczak LJ, et al: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45:970-976, 2013
28. Waldhauer I, Steinle A: NK cells and cancer immunosurveillance. Oncogene 27:5932-5943, 2008
29. Yuan A, Hsiao Y-J, Chen H-Y, et al: Opposite effects of M1andM2macrophage subtypes on lung cancer progression. Sci Rep 5:14273, 2015
30. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307, 2006
31. Huang AC, Postow MA, Orlowski RJ, et al: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65, 2017
32. Guillerey C, Huntington ND, Smyth MJ: Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17:1025-1036, 2016
33. Corrales L, Matson V, Flood B, et al: Innate immune signaling and regulation in cancer immunotherapy. Cell Res 27:96-108, 2017
34. Nik-Zainal S, Davies H, Staaf J, et al: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47-54, 2016
35. Nghiem PT, Bhatia S, Lipson EJ, et al: PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:2542-2552, 2016
36. Kaufman HL, Russell J, Hamid O, et al: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374-1385, 2016
37. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423, 2003
38. Marvel D, Gabrilovich DI: Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest 125:3356-3364, 2015
39. Shukla SA, Rooney MS, Rajasagi M, et al: Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 33:1152-1158, 2015
40. Chiappinelli KB, Strissel PL, Desrichard A, et al: InhibitingDNAmethylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974-986, 2015
41. Galon J, Mlecnik B, Bindea G, et al: Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232:199-209, 2014